BriaCell Imaging Data Show Tumor Regression and Immune Activation in Metastatic Breast Cancer Trial
TipRanks (Wed, 28-Jan 8:25 AM ET)
Globe Newswire (Wed, 28-Jan 7:30 AM ET)
BriaCell Reports Prolonged Survival in Phase 2 Metastatic Breast Cancer Trial
TipRanks (Tue, 27-Jan 8:26 AM ET)
BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients
Globe Newswire (Tue, 27-Jan 7:30 AM ET)
BriaCell Therapeutics Announces Closing of US$30 million Public Offering
Globe Newswire (Thu, 15-Jan 4:05 PM ET)
BriaCell Therapeutics Announces Pricing of $30 million Public Offering
Globe Newswire (Tue, 13-Jan 9:00 PM ET)
Market Chameleon (Tue, 13-Jan 5:31 AM ET)
BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS Patient
Globe Newswire (Tue, 13-Jan 7:30 AM ET)
Globe Newswire (Thu, 18-Dec 7:30 AM ET)
Market Chameleon (Wed, 10-Dec 3:18 AM ET)
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
Briacell Therapeutics Corp. - Common Shares trades on the NASDAQ stock market under the symbol BCTX.
As of January 30, 2026, BCTX stock price declined to $4.30 with 199,455 million shares trading.
BCTX has a beta of 1.08, meaning it tends to be more sensitive to market movements. BCTX has a correlation of 0.02 to the broad based SPY ETF.
BCTX has a market cap of $26.71 million. This is considered a Sub-Micro Cap stock.
Last quarter Briacell Therapeutics Corp. - Common Shares reported $0 in Revenue and -$4.35 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$1.07.
In the last 3 years, BCTX traded as high as $1,214.99 and as low as $4.10.
BCTX has underperformed the market in the last year with a return of -92.3%, while the SPY ETF gained +15.6%. In the last 3 month period, BCTX fell short of the market, returning -62.1%, while SPY returned +2.1%. However, in the most recent 2 weeks BCTX has outperformed the stock market by returning +0.2%, while SPY returned 0.0%.
BCTX support price is $3.89 and resistance is $4.73 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BCTX shares will trade within this expected range on the day.
